The role of Fas/FasL in immunosuppression induced by human tumors Theresa L. WhitesideHannah Rabinowich REVIEW Pages: 175 - 184
Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients R. RidolfiEmanuela FlaminiDino Amadori ORIGINAL ARTICLE Pages: 185 - 193
Dexamethasone induces altered binding of regulatory factors to HLA class I enhancer sequence in MCF-7 breast tumour cell line F. RodriguezMaximino RedondoFrancisco Ruiz-Cabello ORIGINAL ARTICLE Pages: 194 - 200
Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) Birgit C. SchultesRichard P. BaumR. Madiyalakan ORIGINAL ARTICLE Pages: 201 - 212
The combination of interleukin-2 and interferon effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29 Sven BungardD. FliegerUlrich Spengler ORIGINAL ARTICLE Pages: 213 - 220
Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells Øystein Bruserud ORIGINAL ARTICLE Pages: 221 - 228
In vitro characterization of a recombinant 32P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody Mark R. PatrickKerry A. ChesterG. A. Pietersz ORIGINAL ARTICLE Pages: 229 - 237